FINHUB Insights

BMY · Q3 FY25 · Jul 1 – Sep 30, 2025

Bristol Myers Squibb Q3 FY25: where the revenue came from and where it went

Bristol Myers Squibb Q3 FY25: revenue $12.2B (+3% year over year). Net profit $2.2B. Largest cohort International $3.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Oct 30, 2025 10-Q
Sankey diagram of Bristol Myers Squibb's income statement for Q3 FY25: revenue of $12.2 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$12.2B +3% year over year
Gross profit$8.8B 72% margin
Operating profit$-1B -8% margin
Net profit$2.2B 18% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 12.2 100% +3%
International 3.6 30%
Other 2.6 21%
Opdivo 2.5 20%
Orencia 1 8%
Yervoy 0.7 6%
Pomalyst/Imnovid 0.7 6% −25%
Reblozyl 0.6 5%
Revlimid 0.6 5% −59%
Cost of revenue−3.428%
Gross profit8.872% margin−3pp
Research & development−2.521%+1pp
SG&A−1.815%−2pp
Other−5.545%+0pp
Operating profit-1-8% margin+0pp
Tax−0.9
Net profit2.218%+8pp
Filing on EDGAR More quarters of BMY

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters